Rebif (Interferon beta-1a)

DRUG2 trials

Sponsors

Merck KGaA, Darmstadt, Germany

Conditions

Multiple Sclerosis, Relapsing-RemittingRelapsing Multiple Sclerosis (RMS)

Unknown Phase

Post-Authorization Observational Study to Evaluate Cognition and Fatigue in Relapsing-remitting Multiple Sclerosis (RRMS) Patients Treated With Rebif®

CompletedNCT01075880

Merck KGaA, Darmstadt, GermanyMultiple Sclerosis, Relapsing-Remitting

Start: 2009-05-31End: 2013-06-30Updated: 2013-09-06

Non-interventional Study to Assess Adherence to Treatment for Patients With RMS (MAIN-MS)

CompletedNCT02921035

Merck KGaA, Darmstadt, GermanyRelapsing Multiple Sclerosis (RMS)

Start: 2016-06-30End: 2020-07-27Updated: 2022-04-04

Related Papers

Adherence to subcutaneous interferon beta-1a treatment among patients with relapsing multiple sclerosis: the MAIN-MS study

Frontiers in Neurology2023-11-281 citations